PRDM6 promoter methylation as a potential epigenetic biomarker in BRCA-associated ovarian cancer

Background: Ovarian cancer (OC) remains one of the most lethal gynecologic malignancies, primarily due to late-stage diagnosis. Aberrant DNA methylation is critical in tumorigenesis and represents a promising avenue for biomarker development. We hypothesized that PR/SET domain 6 (PRDM6) methylation is associated with breast cancer gene (BRCA) mutation status in OC. Methods: Peripheral blood samples were collected from 387 patients with high-grade serous ovarian cancer, 50 individuals with benign ovarian conditions, and 100 healthy controls. DNA methylation was evaluated using methylation-sensitive restriction enzymes (MSREs) and subsequently analyzed by real-time polymerase chain reaction (PCR). Descriptive statistics were employed to summarize categorical and continuous variables. Associations between PRDM6 methylation and clinical parameters, including BRCA mutation status, cancer antigen 125 (CA-125) levels, and age, were statistically analyzed. Results: PRDM6 methylation was detected in 53.9% of OC patients, 60.0% of individuals with benign ovarian disease, and 37.0% of healthy controls. The methylation frequency in OC patients was significantly higher than in healthy controls (p = 0.005). PRDM6 promoter methylation was detected in 64.8% of BRCA-mutated OC patients compared to 50.3% of BRCA-negative patients, indicating a significant association between BRCA mutation status and PRDM6 methylation (p = 0.016). No significant associations were found between PRDM6 methylation and age, menopausal status, or CA-125 levels. Conclusions: PRDM6 methylation may serve as a non-invasive biomarker for early detection in high-risk populations, particularly in BRCA mutation carriers.

Ovarian cancer; DNA methylation; Epigenetic biomarker; PRDM6 methylation; BRCA mutation

[1] Filho AM, Laversanne M, Ferlay J, Colombet M, Piñeros M, Znaor A, et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. International Journal of Cancer. 2025; 156: 1336–1346.

[2] Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians. 2025; 75: 10–45.

[3] Zhou M, Pi J, Zhao Y. Integrative multi-omics analysis reveals molecular subtypes of ovarian cancer and constructs prognostic models. Journal of Immunotherapy. 2025; 48: 197–208.

[4] Marconato N, Tommasi O, Paladin D, Boscarino D, Spagnol G, Saccardi C, et al. Unraveling homologous recombination deficiency in ovarian cancer: a review of currently available testing platforms. Cancers. 2025; 17: 1771.

[5] He WH, Zhu HJ, Zhang SF, Shu G, Lei H, Yin G, et al. Promoter methylation changes in DNA damage-response genes in ovarian cancer and their correlation with prognosis. Clinical and Experimental Obstetrics & Gynecology. 2024; 51: 109.

[6] Şükrüoğlu Erdoğan Ö, Kılıç Erciyas S, Bilir A, Buğra Tunçer Ş, Akdeniz Ödemiş D, Kurul S, et al. Methylation changes of primary tumors, monolayer, and spheroid tissue culture environments in malignant melanoma and breast carcinoma. BioMed Research International. 2019; 2019: 1407167.

[7] Terp SK, Guldbrandsen K, Stoico MP, Mark LR, Frandsen AP, Dybkær K, et al. Genome-Wide cfDNA methylation profiling reveals robust hypermethylation signatures in ovarian cancer. Cancers. 2025; 17: 2026.

[8] Fu M, Deng F, Chen J, Fu L, Lei J, Xu T, et al. Current data and future perspectives on DNA methylation in ovarian cancer (review). International Journal of Oncology. 2024; 64: 62.

[9] Erdogan OS, Tuncer SB, Kilic S, Odemis DA, Turkcan GK, Celik B, et al. Genome-wide methylation profiles in monozygotic twins with discordance for ovarian carcinoma. Oncology Letters. 2020; 20: 357.

[10] Di Tullio F, Schwarz M, Zorgati H, Mzoughi S, Guccione E. The duality of PRDM proteins: epigenetic and structural perspectives. The FEBS Journal. 2022; 289: 1256–1275.

[11] Schmidt C, Cohen S, Gudenas BL, Husain S, Carlson A, Westelman S, et al. PRDM6 promotes medulloblastoma by repressing chromatin accessibility and altering gene expression. Scientific Reports. 2024; 14: 16074.

[12] Li P, Zheng Y, Wang YS. DEC1 is involved in TGF-β1-induced epithelial-mesenchymal transition of gastric cancer. American Journal of Cancer Research. 2024; 14: 630–642.

[13] Wang Q, Li J, Wang S, Deng Q, An Y, Xing Y, et al. Single-cell transcriptional profiling reveals cellular and molecular divergence in human maternal-fetal interface. Scientific Reports. 2022; 12: 10892.

[14] Tuncer SB, Erdogan OS, Erciyas SK, Saral MA, Celik B, Odemis DA, et al. miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma. Journal of Ovarian Research. 2020; 13: 99.

[15] Wojdacz TK, Dobrovic A. Dobrovic, methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Research. 2007; 35: e41.

[16] Šestáková Š, Šálek C, Remešová H. Remesova, DNA methylation validation methods: a coherent review with practical comparison. Biological Procedures Online. 2019; 21: 19.

[17] Kurdyukov S, Bullock M. Bullock, DNA methylation analysis: choosing the right method. Biology. 2016; 5: 3.

[18] Gonc A, Sukruoglu Erdogan O, Kilic Erciyas S, Celik Demirbas B, Dinc A, Pasin O, et al. CYB5R4 gene methylation as a potential epigenetic marker for ovarian cancer. Clinical Medicine Insights. Oncology. 2025; 19: 11795549251340531.

[19] Feng LY, Yan BB, Huang YZ, Li L. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer. Clinical Epigenetics. 2021; 13: 141.

[20] Zhuang Q, Gu G, Chen J, Tang Z, Wu C, Liu J, et al. Global, regional, and national burden of ovarian cancer among young women during 1990–2019. European Journal of Cancer Prevention. 2025; 34: 1–10.

[21] Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. Journal of Ovarian Research. 2019; 12: 28.

[22] Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. Journal of Clinical Pathology. 2013; 66: 273–281.

[23] Zhang R, Siu MKY, Ngan HYS, Chan KKL. Molecular biomarkers for the early detection of ovarian cancer. International Journal of Molecular Sciences. 2022; 23: 12041.

[24] Wu Y, Wang C, Wang P, Wang C, Zhang Y, Han L. A high-performance microfluidic detection platform to conduct a novel multiple-biomarker panel for ovarian cancer screening. RSC Advances. 2021; 11: 8124–8133.

[25] Barr CE, Njoku K, Owens GL, Crosbie EJ. Urine CA125 and HE4 for the detection of ovarian cancer in symptomatic women. Cancers. 2023; 15: 1256.

[26] Lai X, Li Q, Wu F, Lin J, Chen J, Zheng H, et al. Epithelial-mesenchymal transition and metabolic switching in cancer: lessons from somatic cell reprogramming. Frontiers in Cell and Developmental Biology. 2020; 8: 760.

[27] Wang H, Li J, He J, Liu Y, Feng W, Zhou H, et al. Methyl-CpG-binding protein 2 drives the Furin/TGF-beta1/Smad axis to promote epithelial-mesenchymal transition in pancreatic cancer cells. Oncogenesis. 2020; 9: 76.

[28] Aggarwal V, Montoya CA, Donnenberg VS, Sant S. Interplay between tumor microenvironment and partial EMT as the driver of tumor progression. iScience. 2021; 24: 102113.

[29] Kim K, Ryu TY, Jung E, Han TS, Lee J, Kim SK, et al. Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis. Experimental & Molecular Medicine. 2023; 55: 952–964.

[30] Wanna-Udom S, Terashima M, Suphakhong K, Ishimura A, Takino T, Suzuki T. KDM2B is involved in the epigenetic regulation of TGF-β-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines. Journal of Biological Chemistry. 2021; 296: 100213.

[31] Fog CK, Galli GG, Lund AH. PRDM proteins: important players in differentiation and disease. Bioessays. 2012; 34: 50–60.

[32] Minguillón J, Ramírez MJ, Rovirosa L, Bustamante-Madrid P, Camps-Fajol C, Ruiz de Garibay G, et al. CDK5RAP3, a new BRCA2 partner that regulates DNA repair, is associated with breast cancer survival. Cancers. 2022; 14: 353.

[33] Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. Journal of Clinical Oncology. 2020; 38: 674–685.

[34] Voros C, Varthaliti A, Mavrogianni D, Athanasiou D, Athanasiou A, Athanasiou A, et al. Epigenetic alterations in ovarian function and their impact on assisted reproductive technologies: a systematic review. Biomedicines. 2025; 13: 730.

[35] Oliveira DVNP, Biskup E, O’Rourke CJ, Hentze JL, Andersen JB, Høgdall C, et al. Developing a DNA methylation signature to differentiate high-grade serous ovarian carcinomas from benign ovarian tumors. Molecular Diagnosis & Therapy. 2024; 28: 821–834.

[36] Szafron LA, Iwanicka-Nowicka R, Sobiczewski P, Koblowska M, Dansonka-Mieszkowska A, Kupryjanczyk J, et al. The diversity of methylation patterns in serous borderline ovarian tumors and serous ovarian carcinomas. Cancers. 2024; 16: 3524.

[37] Wever BMM, Schaafsma M, Bleeker MCG, van den Burgt Y, van den Helder R, Lok CAR, et al. Molecular analysis for ovarian cancer detection in patient-friendly samples. Communications Medicine. 2024; 4: 88.

[38] Elsharkawi SM, Elkaffash D, Moez P, El-Etreby N, Sheta E, Taleb RSZ. PCDH17 gene promoter methylation status in a cohort of Egyptian women with epithelial ovarian cancer. BMC Cancer. 2023; 23: 89.

[39] Terp SK, Stoico MP, Dybkær K, Pedersen IS. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review. Clinical Epigenetics. 2023; 15: 24.

[40] Alkan B, Ekinci S, Özcan HN, Üner M, Altunova E, Tekşam Ö, et al. A giant ovarian mucinous cystadenoma in a postmenarchal adolescent girl. The Turkish Journal of Pediatrics. 2025; 67: 282–287.

[41] Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, et al. BRCA methylation testing identifies a subset of ovarian carcinomas without germline variants that can benefit from PARP inhibitor. International Journal of Molecular Sciences. 2020; 21: 9708.

[42] Buttitta F, Di Marino P, Felicioni L, Primavera FC, Ferro B, Zampacorta C, et al. BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report. Pathologica. 2023; 115: 107–110.

[43] Huang X, Shao D, Wu H, Zhu C, Guo D, Zhou Y, et al. Genomic profiling comparison of germline BRCA and Non-BRCA carriers reveals CCNE1 amplification as a risk factor for Non-BRCA carriers in patients with triple-negative breast cancer. Frontiers in Oncology. 2020; 10: 583314.

[44] Hamid AB, Frank LE, Bouley RA, Petreaca RC. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers. PLOS ONE. 2022; 17: e0273736.

[45] Hong L, Li N, Gasque V, Mehta S, Ye L, Wu Y, et al. Prdm6 controls heart development by regulating neural crest cell differentiation and migration. JCI Insight. 2022; 7: e156046.

[46] Zhang H, Wang A, Xu T, Mo X, Zhang Y. Promoter DNA methylation in GWAS-identified genes as potential functional elements for blood pressure: an observational and mendelian randomization study. Frontiers in Genetics. 2021; 12: 791146.

[47] Kaur A, Lim JYS, Sepramaniam S, Patnaik S, Harmston N, Lee MA, et al. WNT inhibition creates a BRCA-like state in Wnt-addicted cancer. EMBO Molecular Medicine. 2021; 13: e13349.

[48] Chen C, Shi Y, Ma J, Chen Z, Zhang M, Zhao Y. Trigonelline reverses high glucose-induced proliferation, fibrosis of mesangial cells via modulation of Wnt signaling pathway. Diabetology & Metabolic Syndrome. 2022; 14: 28.

[49] McKenna JK, Wu Y, Sonkusre P, Sinclear CK, Chari R, Lebensohn AM. The ubiquitin ligase HUWE1 enhances WNT signaling by antagonizing destruction complex-mediated β-catenin degradation and through a mechanism independent of changes in β-catenin abundance. PLOS Genetics. 2025; 21: e1011677.

[50] Wang R, Liu J, Li K, Yang G, Chen S, Wu J, et al. An SETD1A/Wnt/beta-catenin feedback loop promotes NSCLC development. Journal of Experimental & Clinical Cancer Research. 2021; 40: 318.

[51] Shu XS, Geng H, Li L, Ying J, Ma C, Wang Y, et al. The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors. PLOS ONE. 2011; 6: e27346.

[52] Qin Q, Zhou Y, Guo J, Chen Q, Tang W, Li Y, et al. Conserved methylation signatures associate with the tumor immune microenvironment and immunotherapy response. Genome Medicine. 2024; 16: 47.

[53] Zou M, Mangum KD, Magin JC, Cao HH, Yarboro MT, Shelton EL, et al. Prdm6 drives ductus arteriosus closure by promoting ductus arteriosus smooth muscle cell identity and contractility. JCI Insight. 2023; 8: e163454.

[54] Casamassimi A, Rienzo M, Di Zazzo E, Sorrentino A, Fiore D, Proto MC, et al. Multifaceted role of PRDM proteins in human cancer. International Journal of Molecular Sciences. 2020; 21: 2648.

[55] Duran-Ferrer M, Clot G, Nadeu F, Beekman R, Baumann T, Nordlund J, et al. The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome. Nature Cancer. 2020; 1: 1066–1081.

[56] Bian S, Wang Y, Zhou Y, Wang W, Guo L, Wen L, et al. Integrative single-cell multiomics analyses dissect molecular signatures of intratumoral heterogeneities and differentiation states of human gastric cancer. National Science Review. 2023; 10: nwad094.

[57] Lee D, Koo B, Yang J, Kim S. Metheor: ultrafast DNA methylation heterogeneity calculation from bisulfite read alignments. PLOS Computational Biology. 2023; 19: e1010946.